MedTrace Logo

Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer

NCT00984048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2021-06-15

No results posted yet for this study

Summary

This is a multicenter translational study to understand therapeutic resistance in patients undergoing first-line chemotherapy (FOLFOX/Avastin, or FOLFIRI/Avastin) for metastatic colorectal cancer. Tissue samples from liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.

Conditions

Interventions

OTHER

Needle core biopsies of liver metastasis

No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.

Sponsors & Collaborators

  • Exactis Innovation

    collaborator OTHER

  • Terry Fox Research Institute

    collaborator OTHER

  • Fonds de la Recherche en Santé du Québec

    collaborator OTHER_GOV

  • Jewish General Hospital

    lead OTHER

Principal Investigators

  • Gerald Batist, MD · Jewish General Hospital, Segal Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • Belgium
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984048 on ClinicalTrials.gov